25 juni 2022: ASCO 2022

Aanbevolen abstracten specifiek gerelateerd aan longkanker en mesothelioma - asbestkanker door artsen die of zelf voor ASCO werken of door ASCO zijn gevraagd naar hun tips voor belangrijke studies.

Deze abstracten van ASCO 2022 worden aanbevolen door 

Dr. Sarah Goldberg, an Associate Professor of Medicine in the Division of Medical Oncology at the Yale School of Medicine, and an Associate Editor of the PracticeUpdate Center of Excellence for Lung Cancer, recommends the following abstracts being presented at this year's ASCO Annual Meeting, held June 3 through June 7, 2022, in Chicago and simultaneously online.

Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic
Friday, June 3, 2022; 2:00 PM−5:00 PM EDT

9000 Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis. O Akinboro, JJ Vallejo, EC Nakajima, et al

Take-Home Message

  • This study was conducted to determine the impact of the addition of chemotherapy to anti–PD-L1 therapy in patients with advanced NSCLC. Data pooled from 12 randomized controlled trials including a total of 3189 individuals with NSCLC and PD-L1 expression ≥50% were analyzed. The median overall survival of the patients who received IO plus chemotherapy (n=455) and IO only (n=1298) was 25.0 months and 20.9 months, respectively; median PFS was 9.6 and 7.1 months, respectively. The ORR was higher with the combination than with IO alone.
  • The results of this analysis suggest that the combined chemotherapy/IO regimens may be associated with survival outcomes comparable to, or better than, those associated with IO alone.

9002 KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation. AI Spira, GJ Riely, SM Gadgeel, et al

Take-Home Message

  • In this study, the KRAS-G12C inhibitor adagrasib was evaluated in patients with advanced NSCLC who had been treated with platinum-based chemotherapy and anti–PD-1/L1 therapy. After a median follow-up of 12.5 months, the median duration of response was 8.5 months, median progression-free survival was 6.5 months, and median overall survival was 12.6 months. Among the 116 patients enrolled, treatment-related adverse events of any grade occurred in 97.4% and grade ≥3 events occurred in 45.7%.
  • The KRAS-G12C mutation is not uncommon in patients with advanced NSCLC, and adagrasib may offer some meaningful responses and longer progression-free survival.

9004 Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A. KL Reckamp, M Weber Redman, KH Dragnev, et al

9006 Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2. CA Shu, K Goto, Y Ohe, et al

Take-Home Message

  • Updated results of the CHRYSALIS-2 trial of amivantamab and lazertinib in patients with EGFR-mutant NSCLC are presented. The initial results of the combination showed encouraging efficacy in patients whose disease had progressed after treatment with osimertinib and platinum chemotherapy (standard of care). These updated findings build on the original result.
  • The overall response rate (by BICR) was 36% of the 50 evaluable patients in the target population, and the clinical benefit rate was 58%. Treatment-related leading to the discontinuation of either or both amivantamab and lazertinib occurred in 12% and 7% of participants, respectively.

9007 Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20). HA Yu, DSW Tan, EF Smit, et al

9008 Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study. M Krebs, AI Spira, BC Cho, et al

Oral Abstract Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Sunday, June 5, 2022; 10:45 PM−1:45 PM EDT

LBA8507 SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC). CM Rudin, SV Liu, S Lu, et al

Poster Discussion Session: Lung Cancer—Non-Small Cell Metastatic
Monday, June 6, 2022; 2:15 PM−3:45 PM EDT

9016 Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC). DR Camidge, J Bar, H Horinouchi, et al

Clinical Science Symposium: Including the Excluded: Advancing Care for All Patients With Lung Cancer
Monday, June 6, 2022; 5:30 PM−7:00 PM EDT

LBA9009 Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial. JK Sabari, AI Spira, RS Heist, et al

9011 Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study). H Lena, I Monnet, O Bylicki, et al

Plaats een reactie ...

Reageer op "ASCO 2022: aanbevolen abstracten gerelateerd aan longkanker"

Gerelateerde artikelen

Gerelateerde artikelen

ASCO 2021: aanbevolen abstracten >> ASCO 2020: aanbevolen abstracten >> Aanbevolen abstracten van >> Regulier - Longkanker: overzicht >>